A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France.

Autor: Casabianca, Paul1 Paul.Casabianca@bms.com, Massetti, Marc2, Cotte, François-Emery1, Moreau, Romain2, Kassahun, Sarah3, Singh, Prianka4, Kim, Inkyu4, Gaudin, Anne-Françoise1, Piessen, Guillaume5,6,7, Leleu, Henri2
Zdroj: PharmacoEconomics - Open. Sep2024, Vol. 8 Issue 5, p689-699. 11p.
Databáze: Business Source Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje